Daiichi Sankyo Submits a New Drug Application in Japan for CS-8958,
News Feb 01, 2010
CS-8958 is a laninamivir prodrug that is a Long-Acting Neuraminidase Inhibitor.
The drug, developed entirely for the Japanese market by Daiichi Sankyo, will be
in the form of an inhalant that will directly treat the airways of influenza patients.
Clinical studies to date with adults and children suffering from type A or B influenza
viruses have proven CS-8958 to be effective with a single administration.
In non-clinical studies, CS-8958 has also demonstrated that it is efficacious with
the H1N1 and potentially lethal H5N1 (avian influenza) viruses, leading to an
expectation for wide-ranging contributions to influenza treatment in the future.
In November 2009, Daiichi Sankyo began a Phase III clinical study in Japan on
the prophylactic use of CS-8958.
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE
Lab Innovations returns to the NEC, Bimingham , UKNews
Save the date for the UK’s only lab-dedicated exhibition showcase!READ MORE
Comments | 0 ADD COMMENT
International Conference on Biobetters and Regulatory Affairs
Jun 27 - Jun 28, 2018